| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 31 December 2025 |
| for |
| Ridge Pharma Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 31 December 2025 |
| for |
| Ridge Pharma Limited |
| Ridge Pharma Limited (Registered number: 10612687) |
| Contents of the Financial Statements |
| for the Year Ended 31 December 2025 |
| Page |
| Company Information | 1 |
| Report of the Accountants | 2 |
| Balance Sheet | 3 |
| Notes to the Financial Statements | 5 |
| Ridge Pharma Limited |
| Company Information |
| for the Year Ended 31 December 2025 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| ACCOUNTANTS: |
| 12 Park Lane |
| Tilehurst |
| Reading |
| Berkshire |
| RG31 5DL |
| Ridge Pharma Limited |
| Report of the Accountants to the Directors of |
| Ridge Pharma Limited |
| The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies. |
| As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 December 2025 set out on page nil and you consider that the company is exempt from an audit. |
| In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us. |
| 12 Park Lane |
| Tilehurst |
| Reading |
| Berkshire |
| RG31 5DL |
| Date: ............................................. |
| Ridge Pharma Limited (Registered number: 10612687) |
| Balance Sheet |
| 31 December 2025 |
| 2025 | 2024 |
| Notes | £ | £ |
| Fixed assets |
| Tangible assets | 4 |
| Current assets |
| Stocks | 5 |
| Debtors | 6 |
| Prepayments and accrued income |
| Cash at bank and in hand |
| Creditors |
| Amounts falling due within one year | 7 | ( |
) | ( |
) |
| Net current assets |
| Total assets less current liabilities |
| Non-current assets |
| Net assets |
| Capital and reserves |
| Called up share capital | 9 |
| Share premium | 10 |
| Fund raising cost | 10 | ( |
) | ( |
) |
| Retained earnings | 10 | ( |
) | ( |
) |
| Shareholders' funds |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| Ridge Pharma Limited (Registered number: 10612687) |
| Balance Sheet - continued |
| 31 December 2025 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Ridge Pharma Limited (Registered number: 10612687) |
| Notes to the Financial Statements |
| for the Year Ended 31 December 2025 |
| 1. | STATUTORY INFORMATION |
| Ridge Pharma Limited is a |
| 2. | ACCOUNTING POLICIES |
| BASIS OF PREPARING THE FINANCIAL STATEMENTS |
| TURNOVER |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| TANGIBLE FIXED ASSETS |
| Computer equipment | - |
| STOCKS |
| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| TAXATION |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| DEFERRED TAX |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| Ridge Pharma Limited (Registered number: 10612687) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 4. | TANGIBLE FIXED ASSETS |
| Computer |
| equipment |
| £ |
| COST |
| At 1 January 2025 |
| Additions |
| At 31 December 2025 |
| DEPRECIATION |
| At 1 January 2025 |
| Charge for year |
| At 31 December 2025 |
| NET BOOK VALUE |
| At 31 December 2025 |
| At 31 December 2024 |
| 5. | STOCKS |
| 2025 | 2024 |
| £ | £ |
| Closing stock |
| 6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2024 |
| £ | £ |
| Trade debtors |
| Deposit | 3,627 | 3,627 |
| Loan and advances | 137 | - |
| Control Account - Bibby Financial Services | 88,578 | (1,599 | ) |
| 7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2024 |
| £ | £ |
| Bank loans and overdrafts (see note 8) |
| Other loans (see note 8) |
| Trade creditors |
| Deferred Tax B/S | 2,951 | 3,302 |
| Social security |
| VAT | 322,392 | 273,356 |
| Other creditors |
| Pensions Payable | 10,742 | - |
| Accrued expense |
| Accrued Interest on |
| Convertible Loan 2023 |
| Ridge Pharma Limited (Registered number: 10612687) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 8. | LOANS |
| An analysis of the maturity of loans is given below: |
| 2025 | 2024 |
| £ | £ |
| Amounts falling due within one year or on demand: |
| Abcor Working Capital Loan |
| Loan against Stocks |
| 9. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2025 | 2024 |
| value: | £ | £ |
| Ordinary B | £0.01 | 1,254 | 1,254 |
| Ordinary A1 | £0.01 | 848 | 848 |
| Ordinary A2 | £0.01 | 94 | 94 |
| 2,196 | 2,196 |
| 10. | RESERVES |
| Fund |
| Retained | Share | raising |
| earnings | premium | cost | Totals |
| £ | £ | £ | £ |
| At 1 January 2025 | ( |
) | ( |
) | 663,307 |
| Deficit for the year | ( |
) | ( |
) |
| At 31 December 2025 | ( |
) | ( |
) | 537,686 |